Lyric Bio

Lyric Bio is a private, pre-clinical stage biotech founded in 2021 and based in Cambridge, USA, developing a disruptive manufacturing platform for complex biologics. The company's core technology involves laser-printed cellular substrates that enable ultra-high-density cell growth in small-scale bioreactors, aiming to produce over 1,000 doses of immunoglobulin from a single donor versus the current industry standard of approximately 10 plasma donations per dose. By moving from a donation-based supply chain to a controlled, scalable manufacturing process, Lyric seeks to address critical issues of cost, supply stability, and quality in the global Ig market. The company is led by its co-founders, CEO Kayj Shannon and CSO Dr. Melanie Matheu.

Proprietary tissue engineering platform using laser-printed cellular substrates to create ultra-high-density, tissue-mimicking bioreactors for the continuous production of complex human biologics from donor-derived cells.

Lyric Bio's direct competitors are other companies developing alternative immunoglobulin production methods, such as recombinant expression in animal cells (e.g., Apotex, earlier efforts by Merck), though these have faced challenges with product equivalence. More broadly, it competes with the entrenched plasma fractionation industry (CSL, Takeda, Grifols) and platform biomanufacturing companies focusing on cell-free synthesis or other advanced modalities.